DK1121135T3 - Præparater af beta-glucaner og specifikke immunglobuliner - Google Patents

Præparater af beta-glucaner og specifikke immunglobuliner

Info

Publication number
DK1121135T3
DK1121135T3 DK99969030T DK99969030T DK1121135T3 DK 1121135 T3 DK1121135 T3 DK 1121135T3 DK 99969030 T DK99969030 T DK 99969030T DK 99969030 T DK99969030 T DK 99969030T DK 1121135 T3 DK1121135 T3 DK 1121135T3
Authority
DK
Denmark
Prior art keywords
beta
glucans
preparations
specific immunoglobulins
kits
Prior art date
Application number
DK99969030T
Other languages
English (en)
Inventor
Viliam Pavliak
Ali Ibrahim Fattom
Robert B Naso
Original Assignee
Nabi Biopharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nabi Biopharmaceuticals filed Critical Nabi Biopharmaceuticals
Application granted granted Critical
Publication of DK1121135T3 publication Critical patent/DK1121135T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK99969030T 1998-09-14 1999-09-14 Præparater af beta-glucaner og specifikke immunglobuliner DK1121135T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10014698P 1998-09-14 1998-09-14
PCT/US1999/020787 WO2000015238A1 (en) 1998-09-14 1999-09-14 COMPOSITIONS OF β-GLUCANS AND SPECIFIC IGIV

Publications (1)

Publication Number Publication Date
DK1121135T3 true DK1121135T3 (da) 2009-03-23

Family

ID=22278313

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99969030T DK1121135T3 (da) 1998-09-14 1999-09-14 Præparater af beta-glucaner og specifikke immunglobuliner

Country Status (11)

Country Link
US (1) US6355625B1 (da)
EP (1) EP1121135B1 (da)
AT (1) ATE421883T1 (da)
AU (1) AU6033299A (da)
CA (1) CA2344166C (da)
CY (1) CY1109437T1 (da)
DE (1) DE69940371D1 (da)
DK (1) DK1121135T3 (da)
ES (1) ES2321892T3 (da)
PT (1) PT1121135E (da)
WO (1) WO2000015238A1 (da)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610293B1 (en) * 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
US6756361B1 (en) * 1997-10-14 2004-06-29 Nabi Enterococcus antigens and vaccines
US7030101B2 (en) * 1998-09-14 2006-04-18 Nabi Biopharmaceuticals Compositions of β-glucans and specific antibodies
US6936258B1 (en) * 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
CA2434938C (en) * 2001-01-16 2012-02-28 Sloan-Kettering Institute For Cancer Research Compositions of glucan and a monoclonal antibody which exhibit an enhancement of the anti tumor activity of the antibody
US7507724B2 (en) 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7786094B2 (en) * 2001-10-09 2010-08-31 Biopolymer Engineering, Inc. Use of beta-glucans against biological warfare weapons and pathogens including anthrax
AU2003295326A1 (en) * 2002-09-04 2004-04-23 Cancer therapy using beta glucan and antibodies
US20060165700A1 (en) * 2002-09-04 2006-07-27 Ostroff Gary R Cancer therapy using whole glucan particles and antibodies
CN1964722A (zh) * 2004-05-10 2007-05-16 生物聚合物工程有限公司 与抗生素、疫苗和病毒单克隆抗体组合的全葡聚糖颗粒
EP1804833A2 (en) 2004-09-22 2007-07-11 GlaxoSmithKline Biologicals SA Staphylococcal immunogenic compositions
US20060134141A1 (en) * 2004-12-14 2006-06-22 Nabi Biopharmaceuticals Glycoconjugate vaccines containing peptidoglycan
WO2006076058A1 (en) * 2005-01-10 2006-07-20 Nabi Biopharmaceuticals Method of treating staphylococcus aureus infection
US20060228368A1 (en) * 2005-04-07 2006-10-12 Nabi Biopharmaceuticals Method of protecting against staphylococcal infection
WO2006119395A2 (en) * 2005-05-03 2006-11-09 Biopolymer Engineering, Inc. Combination of a beta-glucan and an egf receptor antagonist for the treatment of cancer and infection
CA2607004C (en) * 2005-05-05 2016-01-26 Sensient Flavors Inc. Production of beta-glucans and mannans
CN101218252A (zh) 2005-06-13 2008-07-09 Nabi生物制药公司 Panton-valentine杀白细胞素用于治疗和预防葡萄球菌感染的用途
GB0526038D0 (en) 2005-12-21 2006-02-01 Glaxosmithkline Biolog Sa Immunogenic composition
US8323644B2 (en) 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
EP2476433A1 (en) 2006-03-30 2012-07-18 GlaxoSmithKline Biologicals S.A. Immunogenic composition
WO2007145689A1 (en) 2006-06-12 2007-12-21 Nabi Biopharmaceuticals Use of alpha-toxin for treating and preventing staphylococcus infections
EP2208787A1 (en) 2009-01-19 2010-07-21 Université de Liège A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted
WO2010085590A1 (en) 2009-01-23 2010-07-29 Biosynexus Incorporated Opsonic and protective antibodies specific for lipoteichoic acid gram positive bacteria
AU2010271116B2 (en) 2009-04-03 2015-08-13 University Of Chicago Compositions and methods related to Protein A (SpA) variants
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
US8808699B2 (en) 2010-04-05 2014-08-19 The University Of Chicago Compositions and methods related to protein A (SpA) antibodies as an enhancer of immune response
US8431687B2 (en) 2010-05-05 2013-04-30 New York University Staphylococcus aureus leukocidins, therapeutic compositions, and uses thereof
ES2655701T3 (es) 2010-07-02 2018-02-21 The University Of Chicago Composiciones y métodos relacionados con variantes de la proteína A (SpA)
JP5793194B2 (ja) 2010-09-09 2015-10-14 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 感染防御ブドウ球菌抗原が関与する方法および組成物
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
CA2839558A1 (en) 2011-06-19 2012-12-27 New York University Leukotoxin e/d as a new anti-inflammatory agent and microbicide
CA2839554C (en) 2011-06-19 2023-09-26 New York University Methods of treating and preventing staphylococcus aureus infections and associated conditions
CA2845259A1 (en) 2011-08-15 2013-02-21 The University Of Chicago Compositions and methods related to antibodies to staphylococcal protein a
ES2806945T3 (es) 2012-04-26 2021-02-19 Univ Chicago Antígenos de coagulasa estafilocócica y métodos para su uso
CA2910320A1 (en) 2012-04-26 2013-10-31 University Of Chicago Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease
EP2854530B1 (en) 2012-04-30 2018-01-03 Biothera, Inc. Compositions for beta-glucan immunotherapy
GB201310008D0 (en) 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
MX2017007652A (es) 2014-12-10 2017-10-11 Glaxosmithkline Biologicals Sa Metodo de tratamiento.
US11214600B2 (en) 2016-02-12 2022-01-04 The University Of Chicago Compositions and methods related to antibodies that neutralize coagulase activity during Staphylococcus aureus disease
WO2018156888A1 (en) 2017-02-24 2018-08-30 Biothera Pharmaceuticals, Inc. Beta glucan immunopharmacodynamics
WO2021067785A1 (en) 2019-10-02 2021-04-08 Janssen Vaccines & Prevention B.V Staphylococcus peptides and methods of use
WO2023192998A1 (en) 2022-04-01 2023-10-05 Icahn School Of Medicine At Mount Sinai Treating orthopedic injury with a vector driving expression of acid ceramidase

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4900722A (en) * 1985-08-19 1990-02-13 Bioglucans, L.P. Methods and compositions for prophylactic and therapeutic treatment of infections
US4739046A (en) * 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan
US5032401A (en) * 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
CA2040374C (en) * 1990-07-06 1998-06-16 Gunnar Rorstad Process for enhancing the resistance of aquatic animals to disease
ES2198405T3 (es) * 1991-11-22 2004-02-01 Nabi Biopharmaceuticals Antigenos de superficie de tipo i asociados a staphylococcus epidermis.
WO1996014873A2 (en) * 1994-11-16 1996-05-23 Sri International COVALENTLY BOUND β-GLUCAN CONJUGATES IN TARGETED DELIVERY
US5785975A (en) * 1995-06-26 1998-07-28 Research Triangle Pharmaceuticals Adjuvant compositions and vaccine formulations comprising same
US5770208A (en) * 1996-09-11 1998-06-23 Nabi Staphylococcus aureus B-linked hexosamine antigen

Also Published As

Publication number Publication date
WO2000015238A9 (en) 2000-10-12
CA2344166A1 (en) 2000-03-23
US6355625B1 (en) 2002-03-12
ATE421883T1 (de) 2009-02-15
EP1121135B1 (en) 2009-01-28
AU6033299A (en) 2000-04-03
EP1121135A4 (en) 2005-03-16
DE69940371D1 (de) 2009-03-19
CY1109437T1 (el) 2014-08-13
WO2000015238B1 (en) 2000-08-31
PT1121135E (pt) 2009-03-05
EP1121135A1 (en) 2001-08-08
ES2321892T3 (es) 2009-06-12
CA2344166C (en) 2008-11-18
WO2000015238A1 (en) 2000-03-23

Similar Documents

Publication Publication Date Title
DK1121135T3 (da) Præparater af beta-glucaner og specifikke immunglobuliner
PT966447E (pt) Moleculas pequenas uteis no tratamento de doencas inflamatorias
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
ATE148130T1 (de) Typ-iv-dipeptidyl-aminopeptidase-inhibitoren
NO995349L (no) Multivalent vaksinasjonssammensetning med blandet baerer
BR0013771A (pt) Composto, métodos de tratamento de uma infecção viral em um mamìfero, de inibir a transcriptase reversa do hiv, e de prevenção da infecção do hiv ou de tratar a infecção do hiv, uso de um composto, e, composição farmacêutica
EP1362127A4 (en) SERPIN-BASED MEDICINAL PRODUCTS FOR THE TREATMENT OF HIV INFECTION AND THE USE THEREOF
DK0951473T3 (da) Cyclosporinderivat, fremstilling af dette og farmaceutiske præparater indeholdende dette
TR199900856T2 (xx) Bron�la ilgili terapi maddeleri olarak benzonaftiridinler
AU2001235006A1 (en) Prophylactic and therapeutic monoclonal antibodies
EA200000196A1 (ru) Универсальная плазма крови
ATE279940T1 (de) Behandlung und prävention von helicobacter- infektionen
BR9713312A (pt) Método de produção de imunidade ativa com conjugado de vacina.
BR0109164A (pt) Anticorpos monoclonais para o receptor humano para ldl, produção e uso dos mesmos
DK1042492T3 (da) Humaniserede monoklonale antistoffer der beskytter med Shiga-toksininducerede sygdomme
ATE317263T1 (de) Diphosphonat derivate von therapeutisch wirksamen stoffen
DK0633928T3 (da) Mikroorganismer, deres fremstilling og anvendelse
DE69928523D1 (de) Verotoxin b untereinheit zur immunisierunug
BR0016616A (pt) Microrganismos atenuados para o tratamento de infecção
TR199802452T2 (xx) Potasyum klavulanat�n preparasyonu i�in geli�tirilmi� bir proses.
BR0308734A (pt) Composto, composição farmacêutica, uso do composto, e, método para prevenir ou tratar infecção
DK1159426T3 (da) Kloning og udtryk af Haemophilus somnus transferrin-bindende proteiner
DK1064294T3 (da) 5-imino-13-deoxyanthracyclin-derivater, deres vendelse og fremgangsmåde til fremstilling af disse
NO982151D0 (no) Hemoregulatoriske forbindelser
IT1276454B1 (it) Metodo per la diagnosi di infezioni helycobacter pylori e relativo corredo diagnostico.